Lexeo Therapeutics, Inc. announced positive interim results from the ongoing Phase I/II HEROIC-PKP2 clinical trial of its gene therapy candidate LX2020, designed to treat plakophilin-2 arrhythmogenic cardiomyopathy (PKP2-ACM). The trial involves ten participants, with nine completing at least 12 months of follow-up as of the October 15, 2026 data cutoff.
According to the company, treatment with LX2020 was generally well tolerated across all ten participants. The data indicates clinically meaningful reductions in arrhythmia burden in high-dose cohorts. Specifically, participants in these cohorts experienced an 80% mean reduction in non-sustained ventricular tachycardia (NSVT) and a 44% mean reduction in premature ventricular contractions (PVC) at the latest assessment. Additionally, five of seven participants in the high-dose groups reported symptom improvement on the Patient Global Impression of Change scale, and preliminary evidence suggests stabilization or improvement in cardiac function assessed by cardiac MRI.
Safety monitoring revealed no clinically significant complement activation, and no participants discontinued the study. One Grade 3 serious adverse event of ventricular tachycardia was observed three months post-dosing; the company noted this event was consistent with the natural course of PKP2-ACM and was successfully treated.
Lexeo also provided an update on regulatory discussions with the U.S. Food and Drug Administration. The FDA has indicated it is open to using guideline-defined NSVT as a primary surrogate endpoint in a pivotal study to support a potential accelerated approval. The company plans to finalize the pivotal study design, statistical analysis plan, and confirmatory strategy in the first half of 2027 and expects to initiate the pivotal study in the second half of 2027.
Separately, Lexeo reported its financial results for the third quarter of 2026. As of September 30, 2026, the company held $219.1 million in cash, cash equivalents, and investments, which it expects to fund operations into 2028. Research and Development expenses for the quarter were $34.5 million, compared to $15.7 million in the prior year, driven largely by the acquisition of Mantle Therapeutics and a development milestone related to its LX2006 program. General and Administrative expenses were $5.9 million for the quarter. The company reported a net loss of $38.3 million, or $0.43 per share, for the three months ended September 30, 2026.